SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to outsmart stubborn blood cancers
Disease control Not yet recruitingThis study tests a new drug, NX-5948, combined with other medicines for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to prior treatment. About 150 adults will participate to see if the combination is safe and effective. The go…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New hope for hard-to-treat blood cancers: phase 3 trial compares two targeted drugs
Disease control Not yet recruitingThis study tests a new drug, NX-5948, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to a prior targeted therapy. About 620 adults will be randomly assigned…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug duo aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis study tests two oral drugs, nemtabrutinib and venetoclax, given together as the first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination can clear even the tiniest traces of cancer from the …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug cocktail aims to deeply suppress blood cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (acalabrutinib, venetoclax, and tafasitamab) in 35 adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combo is safe and can achieve a complete response with undetecta…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Immune cell army targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) to help the body fight the…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
CLL patients may pause cancer drugs without relapse
Disease control Not yet recruitingThis study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. Researchers will track how long patients stay cancer-free without treatment, and whether stopping le…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC